Seeking Alpha

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
Seeking Alpha

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best ...

REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target ...